Fuji Pharma Co., Ltd. announced consolidated earnings results for the year ended September 30, 2019. For this period, the company reported Net sales of JPY 36,279 million compared to JPY 37,909 million a year ago. Operating profit was JPY 4,173 million compared to JPY 4,391 million a year ago. Ordinary profit was JPY 4,169 million compared to JPY 4,472 a year ago. Earnings per share was JPY 97.04 compared to JPY 112.68 a year ago. Profit attributable to owners of parent was JPY 2,962 million compared to JPY 3,372 million a year ago.

For the Six months ending March 31, 2020, the company expected net sales to be JPY 16,647 million. Operating profit to be JPY 1,209 million. Ordinary profit to be JPY 1,174 million. Earnings per share to be JPY 25.09. Profit attributable to owners of parent to be JPY 781 million.

For the year ending September 30, 2020, the company expected net sales to be JPY 33,830 million. Operating profit to be JPY 2,571 million. Ordinary profit to be JPY 2,501 million. Earnings per share to be JPY 53.44 . Profit attributable to owners of parent to be JPY 1,664 million.

The company announced dividend for the fiscal year ending September 30, 2019 of JPY 15 per share compared to JPY 14 per share a year ago. The payable date is December 20,2019.

The company provided dividend Guidance for the Second quarter of 2020. For the period, the company expected dividend of JPY 14 per share compared to JPY 14 per share paid in the same period ago.

The company provided year end dividend Guidance for the year ending September 30, 2020 . For the period, the company expected year end dividend of JPY 15 per share compared to JPY 15 per share paid in the same period ago.